Single-Cell Transcriptome in Chronic Myeloid Leukemia: Pseudotime Analysis Reveals Evidence of Embryonic and Transitional Stem Cell States
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy, characterized by acquisition of the t(9;22) translocation leading to Ph1 chromosome and its counterpart BCR-ABL oncogene, in a very primitive hematopoietic stem cell [1]. CML is a model of targeted therapies as the proof of concept of the feasibility of targeting the tyrosine kinase (TK) activity BCR-ABL using TK inhibitors (TKIs) has been found to lead to major responses and remissions [2]. The use of imatinib and, later, second-generation [3,4] and third-generation [5] TKI therapies has changed the natural history of the disease and prolonged overall survival [6] .
Source: Experimental Hematology - Category: Hematology Authors: Sarah Pagliaro, Christoph Desterke, Herve Acloque, Jean Claude Chomel, Lucas de Souza, Patricia Hugues, Frank Griscelli, Adlen Foudi, Annelise Bennaceur-Griscelli, Ali G. Turhan Tags: Regular submission Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Mergers and Aquisitions | Stem Cell Therapy | Stem Cells | Translocation